CNS Pharmaceuticals Files S-1/A Amendment

TL;DR

CNS Pharma filed an S-1/A amendment, looks like they're still prepping for a public offering.

AI Summary

CNS Pharmaceuticals, Inc. filed an S-1/A amendment on May 12, 2025, for its registration statement. The company, incorporated in Nevada, is in the pharmaceutical preparations industry and is based in Houston, Texas. This filing is an amendment to a previous registration, indicating ongoing efforts to register securities.

Why It Matters

This filing indicates CNS Pharmaceuticals is actively working through the process of registering securities, which is a necessary step for public offerings or other significant capital-raising activities.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with companies seeking to raise capital, which can involve inherent risks for investors depending on the company's stage and the specifics of the offering.

Key Numbers

• 333-286529 — SEC Registration Number (Identifies the specific registration statement being amended.)
• 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Registrant
• May 12, 2025 (date) — Filing Date
• 333-286529 (registration_number) — SEC Registration Number
• John Climaco (person) — Chief Executive Officer
• Houston, TX (location) — Principal Executive Offices

FAQ

From the Filing

0001683168-25-003362.txt : 20250512 0001683168-25-003362.hdr.sgml : 20250512 20250512060310 ACCESSION NUMBER: 0001683168-25-003362 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 14 FILED AS OF DATE: 20250512 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-286529 FILM NUMBER: 25932385 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 S-1/A 1 cns_s1a1.htm AMENDMENT NO. 1 TO FORM S-1 CNS Pharmaceuticals, Inc. S-1 true client made edits. 0001729427 S-1/A 0001729427 2025-05-12 2025-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares As filed with the Securities and Exchange Commission on May 12, 2025.   Registration No. 333-286529   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter)   Nevada 2834 82-2318545 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number)   2100 West Loop South , Suite 900 Houston , TX 77027 (800) 946-9185 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)   Mr. John Climaco Chief Executive Officer 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)   Copies to:   Cavas S. Pavri Johnathan Duncan ArentFox Schiff LLP 1717 K Street NW Washington, DC 20006 Telephone: (202) 724-6847 Fax: (202) 778-6460 Ron Ben-Bassat Eric Victorson Sullivan & Worcester LLP 1251 Avenue of the Americas New York, NY 10020 Telephone: (212) 660-3000   Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.   If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒   If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐   If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐   If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller